PSTV PLUS THERAPEUTICS, INC.

Nasdaq plustherapeutics.com


$ 0.69 $ 0.03 (3.84 %)    

Tuesday, 14-Oct-2025 19:38:04 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 0.7031
$ 0.65
$ 0.64 x 100
$ 0.71 x 145
$ 0.64 - $ 0.71
$ 0.16 - $ 2.31
8,785,763
na
69.79M
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-30-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 10-31-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 04-20-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 10-20-2022 09-30-2022 10-Q
13 07-21-2022 06-30-2022 10-Q
14 04-21-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 10-21-2021 09-30-2021 10-Q
17 07-22-2021 06-30-2021 10-Q
18 04-22-2021 03-31-2021 10-Q
19 02-22-2021 12-31-2020 10-K
20 10-22-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-15-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-24-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-plus-therapeutics-raises-price-target-to-21

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and raises the price target from ...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 why-merus-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...

 sp-500-falls-1-accenture-posts-upbeat-earnings

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Thursday. The Dow traded ...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...

 nasdaq-down-over-1-us-initial-jobless-claims-fall

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market open...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ: PSTV) with a Buy and maintains $5 price target.

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

 plus-therapeutics-announces-national-coverage-agreement-with-unitedhealthcare-for-cns-cancer-diagnostic-kit

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has signed a national agreement with U...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.

 plus-therapeutics-secures-additional-19m-cprit-payment-under-176m-non-dilutive-grant

Non-dilutive payment is part of $17.6 million award granted for the Company's leptomeningeal cancer targeted radiotherapeut...

 d-boral-capital-maintains-buy-on-plus-therapeutics-maintains-5-price-target

D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.

 d-boral-capital-upgrades-plus-therapeutics-to-buy-announces-5-price-target

D. Boral Capital analyst Jason Kolbert upgrades Plus Therapeutics (NASDAQ:PSTV) from Hold to Buy and announces $5 price target.

 maxim-group-maintains-buy-on-plus-therapeutics-lowers-price-target-to-3

Maxim Group analyst Jason McCarthy maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $4 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION